Table 2.
Ongoing studies for metastatic uveal melanoma in the U.S.
| Clinical trials No. | Treatment | Phase | N | Status | Primary end point |
|---|---|---|---|---|---|
| NCT01473004 | Cabozantinib (MET inhibitor) vs Temozolomide | II | 69 | Recruiting | Progression-free survival at 4 months |
| NCT01585194 | Ipilimumab + nivolumab (combination checkpoint blockade) | II | 52 | Recruiting | Objective response rate |
| NCT01814046 | Adoptive T cell therapy + high dose IL-2 vs adoptive T cell therapy (T cell therapy) | II | 57 | Recruiting | Objective response rate |
| NCT01252251 | Everolimus (mTOR inhibitor) + pasireotide (somatostatin analog) | II | 25 | Recruiting | Clinical benefit rate |
| NCT01587352 | Vorinostat (histone deacetylase inhibitor) | II | 40 | Recruiting | Objective response rate |
| NCT01979523 | Trametinib (MEK inhibitor) vs Trametinib + GSK2141795 (AKT inhibitor) | II | 80 | Recruiting | Progression-free survival |
| NCT02359851 | Pembrolizumab (anti-PD1 antibody) | II | 29 | Recruiting | Objective response rate |
| NCT02273219 | AEB071 (protein kinase C inhibitor) + BYL719 (PI3Kα inhibitor) | I | 50 | Recruiting | Maximum tolerated dose |
| NCT02363282 | Glembatumumab vedotin (antibody-drug conjugate) | II | 34 | Not yet open | Objective response rate |
| NCT01730157 | Radioembolization (Y90) with Ipilimumab (anti-CTLA4 antibody) | 0 | 12 | Active, not recruiting | Toxicity, hepatic response rate |